Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas

PLoS One. 2018 Feb 28;13(2):e0193213. doi: 10.1371/journal.pone.0193213. eCollection 2018.

Abstract

Objective: To study the presence of 9p deletion and p16, cyclin D1 and Myc expression and their respective diagnostic and prognostic interest in oligodendrogliomas.

Methods: We analyzed a retrospective series of 40 consecutive anaplastic oligodendrogliomas (OIII) from a single institution and compared them to a control series of 10 low grade oligodendrogliomas (OII). Automated FISH analysis of chromosome 9p status and immunohistochemistry for p16, cyclin D1 and Myc was performed for all cases and correlated with clinical and histological data, event free survival (EFS) and overall survival (OS).

Results: Chromosome 9p deletion was observed in 55% of OIII (22/40) but not in OII. Deletion was highly correlated to EFS (median = 29 versus 53 months, p<0.0001) and OS (median = 48 versus 83 months, p<0.0001) in both the total cohort and the OIII population. In 9p non-deleted oligodendrogliomas, p16 hyperexpression correlated with a shorter OS (p = 0.02 in OII and p = 0.0001 in OIII) whereas lack of p16 expression was correlated to a shorter EFS and OS in 9p deleted OIII (p = 0.001 and p = 0.0002 respectively). Expression of Cyclin D1 was significantly higher in OIII (median expression 45% versus 14% for OII, p = 0.0006) and was correlated with MIB-1 expression (p<0.0001), vascular proliferation (p = 0.002), tumor necrosis (p = 0.04) and a shorter EFS in the total cohort (p = 0.05). Hyperexpression of Myc was correlated to grade (median expression 27% in OII versus 35% in OIII, p = 0.03), and to a shorter EFS in 9p non-deleted OIII (p = 0.01).

Conclusion: Chromosome 9p deletion identifies a subset of OIII with significantly worse prognosis. The combination of 9p status and p16 expression level identifies two distinct OIII populations with divergent prognosis. Hyperexpression of Bcl1 and Myc appears highly linked to anaplasia but the prognostic value is unclear and should be investigated further.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain Neoplasms* / genetics
  • Brain Neoplasms* / metabolism
  • Brain Neoplasms* / mortality
  • Brain Neoplasms* / pathology
  • Chromosome Deletion*
  • Chromosomes, Human, Pair 9 / genetics
  • Chromosomes, Human, Pair 9 / metabolism
  • Cyclin D1* / biosynthesis
  • Cyclin D1* / genetics
  • Cyclin-Dependent Kinase Inhibitor p16* / biosynthesis
  • Cyclin-Dependent Kinase Inhibitor p16* / genetics
  • Disease-Free Survival
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Male
  • Middle Aged
  • Oligodendroglioma* / genetics
  • Oligodendroglioma* / metabolism
  • Oligodendroglioma* / mortality
  • Oligodendroglioma* / pathology
  • Proto-Oncogene Proteins c-myc* / biosynthesis
  • Proto-Oncogene Proteins c-myc* / genetics
  • Survival Rate

Substances

  • CCND1 protein, human
  • CDKN2A protein, human
  • Cyclin-Dependent Kinase Inhibitor p16
  • MYC protein, human
  • Proto-Oncogene Proteins c-myc
  • Cyclin D1

Supplementary concepts

  • Chromosome 9p Deletion Syndrome

Grants and funding

This work was supported by grants from Fondation du CHU de Québec (grant #2885) to SS. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.